On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVID (nirmatrelvir [PF-07321332] tablets and ritonavir tablets), to 95 low- and middle-income countries, pending authorization or approval.

This included all low- and lower-middle-income countries and some upper-middle-income countries in Sub-Saharan Africa as well as countries that had transitioned from lower-middle to upper-middle-income status in the last five years, accounting for approximately 53% of the world’s population.

Financial details of the agreement were not disclosed. Pfizer expects supply to be available to support orders in April 2022, and supply will continue throughout 2022, pending regulatory authorization or approval and according to country needs. All low- and lower-middle-income countries will be offered the treatment courses at the not-for-profit price while upper-middle-income countries will pay the price defined in Pfizer’s tiered pricing approach.